Fibroblast growth factor 19 is a protein that in humans is encoded by the FGF19 gene. [5] It functions as a hormone, regulating bile acid synthesis, with effects on glucose and lipid metabolism. Reduced synthesis, and blood levels, may be a factor in chronic bile acid diarrhea and in certain metabolic disorders. [6] [7]

成纤维细胞生长因子19（FGF19）亚家族包含FGF19、FGF21、FGF23三种蛋白，它们对FGFR1c、2c、3c和4受体显示活性，但不能与FGFR1b、2b和3b受体结合。 与经典的FGF亚家族成员不同，FGF19亚家族蛋白仅具有微弱的肝素结…

2024年12月25日 · FGF19 (Fibroblast Growth Factor 19) is a Protein Coding gene. Diseases associated with FGF19 include Alagille Syndrome 1 and Functional Diarrhea . Among its related pathways are Apoptotic Pathways in Synovial Fibroblasts and GPCR Pathway .

FGF19 (FGF15 in rodents), a member of the endocrine FGF family, is an intestinal hormone involved in the regulation of bile acid, glucose and lipid metabolism to maintain systemic homeostasis. FGF19/15 has the potential to treat a variety of chronic diseases, including obesity, diabetes and ma-lignant cancers.

研究显示， ponatinib靶向FGF19/FGFR4轴，通过增强索拉非尼治疗的HCC中ros相关的凋亡，可以克服索拉非尼的HCC耐药性。 我国是肝癌大国，肝细胞癌（HCC）是占比最高的肝癌类型。 研究发现，大约30%的HCC患者存在成纤维细胞生长因子19（FGF19）-成纤维细胞生长因子受体4（FGFR4）信号通路异常。 成纤维细胞生长因子（FGF）信号通路在很…

成纤维细胞生长因子19(fibroblast growth factor 19,FGF19)是在回肠末端特异性合成并分泌的细胞因子,属于FGFs的特殊成员之一。 近年来自动物及细胞学的研究发现,FGF19不仅在胆汁酸代谢的调节中发挥重要作用,而且与多种心血管疾病危险因素密切相关。

2024年8月19日 · fgf19也可能是筛查肺癌的新诊断指标，与fgfr4结合驱动肺鳞状细胞癌（lsq）的进展。 为FGF19驱动的LSQ中使用阻断FGF19/FGFR4信号轴疗法提供了新思路。 （ 数据来源Li F, et al. Oncogene. 2020 ）

2019年6月14日 · Fibroblast growth factor (FGF) 15 in mice and its human orthologue FGF19 (together denoted FGF15/19) are gut hormones that control homeostasis of bile acids and glucose...

本综述旨在提供针对胆汁淤积、代谢和癌症疾病患者靶向 FGF19-FGFR4 信号通路的类似物和拮抗剂临床开发的最新信息。 我们还将分析潜在的安全性和机制问题，这些问题应指导未来的研究和高级试验。 Human fibroblast growth factor 19 (FGF19, or FGF15 in rodents) plays a central role in controlling bile acid (BA) synthesis through a negative feedback mechanism.

Several mitogenic, cytoprotective and angiogenic therapeutic applications of FGFs are already being explored, and the recent discovery of the crucial roles of the endocrine-acting FGF19 subfamily in bile acid, glucose and phosphate homeostasis has sparked renewed interest in the pharmacological potential of this family.